WARRANTS - Marpai Health Warrants (Details) - USD ($) |
1 Months Ended | 9 Months Ended | |||
---|---|---|---|---|---|
Feb. 28, 2021 |
Sep. 30, 2021 |
Sep. 30, 2020 |
Apr. 01, 2021 |
Jan. 17, 2020 |
|
Class of Warrant or Right [Line Items] | |||||
Cash payment for purchase of warrants | $ 53,333 | $ 213,828 | |||
Marpai Health Warrants | |||||
Class of Warrant or Right [Line Items] | |||||
Warrants to purchase common shares | 926,349 | 1,290,814 | 364,465 | ||
Warrants exercise price | $ 7.90 | $ 1.43 | |||
Fair value of the warrants | $ 213,828 | ||||
Cash payment for purchase of warrants | $ 50,833 |
X | ||||||||||
- Definition Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Exercise price per share or per unit of warrants or rights outstanding. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition The fair value of shares that would be issued, determined under the conditions specified in the contract if the settlement were to occur at the reporting date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|